Jeffrey L. Dage

ARSA: an autonomous research scientist for target nomination in Alzheimer's disease and related dementias

ARSA generates evidence-based target shortlists for Alzheimer's disease and related dementias by integrating natural language research interests with molecular data and cross-cohort evidence.

Molecular mechanisms underlying amyloid lowering by aducanumab: differential and comparative effects of sex and IgG reveal the post-treatment disease brain

This study examines the molecular effects of aducanumab treatment in 5XFAD mice, revealing sex-dependent and IgG-mediated changes in amyloid and associated pathways.

Optimization and Characterization of SHIP1 Ligands for Cellular Target Engagement and Activity in Alzheimer's Disease Models

This study identifies SHIP1 ligands with brain exposure and in vivo activity in Alzheimer's models, showing target engagement and reduced neuroinflammation.

Independent information from PET, CSF and plasma biomarkers of tau pathology in Alzheimer's disease

The paper examines the independent associations of PET, CSF, and plasma tau biomarkers with Alzheimer's disease markers, finding that CSF and plasma p-tau181/p-tau217 are more linked to early AD markers, while tau-PET is strongly associated with cognitive and neurodegenerative progression.

Cross-Platform Validation of Neurotransmitter Release Impairments in Schizophrenia Patient-Derived NRXN1-Mutant Neurons

This study validates that heterozygous NRXN1 deletions impair neurotransmitter release in human neurons across multiple labs, suggesting a human-specific synaptic dysfunction relevant for schizophrenia drug discovery.

Large eQTL meta-analysis reveals differing patterns between cerebral cortical and cerebellar brain regions

This paper performs a large-scale eQTL meta-analysis across cerebral cortical and cerebellar brain regions, identifying distinct eQTL patterns and demonstrating improved power over existing studies.